Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

NCT02667574 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: ERIVEDGE

Sponsor

University Hospital, Lille

Collaborators

[object Object]